February 1, 2012
More therapeutic candidates are nearing approval, and the many classes of oligonucleotide therapeutics in development are creating great excitement. The peptide pipeline is vital, with candidates that could be blockbusters. To tap into this market and get the best information to move your program forward, there is no better place to meet than at TIDES.
Manufacturers face tremendous pressure to keep drug costs down with uncertainty about regulatory expectations for analytics and GMP manufacturing issues. The industry needs to know about regulatory changes as well as risks to supply-chain integrity. This conference can help you learn how to proceed. Learn lessons from peers who have been through the development process so that you can move your manufacturing process program forward efficiently. Hear about the latest technologies that can help you save time, reduce costs, and increase yields. Meet potential collaborators and business partners in the best networking forum for the oligonucleotide and peptide manufacturing industry.
See updates on clinical progress of the most promising peptide and oligonucleotide therapeutics in reports from Novartis, Ironwood, Affymax, Regado, Alnylam, Dynavax, and Excaliard. Benchmark your development activities against case studies from Pfizer Radius Health, Prosensa, Emergent BioSolutions, Bachem, and RAPID Laboratories. Discover more patient-friendly delivery routes from Alnylam, TransDerm, Dynavax, Pfizer, MannKind Corporation, and Amunix. Play an active role in moving the industry forward by learning and interacting in strategy discussion forums on critical issues.
Program Tracks
Oligonucleotide and Peptide Manufacturing Technology and Product Development: Case studies on CMC challenges, early drug-product development, and delivery alternatives
Oligonucleotide Therapeutics Discovery: Improving drug-like properties to accelerate preclinical and clinical development
Peptide Discovery and Development: Exploiting peptides as intracellular drugs, novel scaffolds, and improved molecules for therapeutic development
Nucleic Acids Technologies for Molecular Diagnostics: Accelerating product development through cutting-edge regulatory, business, and technology strategies
Strategic Discussion Forums will address:
Quality By Design, Revisited (sponsored by Avecia)
When to Choose Recombinant vs. Synthetic Production of Peptides: The Complexities of a “Simple” Decision
The Oligo Supply Chain: How Strong Is the Weakest Link? (sponsored by Agilent Technologies)
Impurities: At What Stage Do You Need to Qualify Impurities?
Preclinical Evaluation of Immunomodulatory Effects of Oligonucleotides and Formulations: Challenges and Strategies
Strategies for Formulation Transition
Alternative Delivery Platforms for Oligonucleotide and Peptide Therapeutics
Conjugation: From a One-Off Approach to a Platform Technology — Pros and Cons
Five Preconference Courses
A preconference forum on CMO–Sponsor Relationships in Therapeutic Development featuring panel discussions with representatives of major CMOs and sponsors is free for TIDES delegates.
Two Full-Day Courses:
Business and Operational Strategies for Successful Oligonucleotide Development
Peptide Manufacturing and Analysis: A Basic Tutorial
Three Half-Day Courses:
Early Drug Product Development
Peptide–Oligonucleotide Conjugation Strategies
Oligonucleotide Lead Discovery
Keynotes
Plan for the future with these dynamic keynote presentations:
A bright forecast for oligonucleotide therapeutics despite recent pharma changes by Art Krieg (Atlas Ventures)
An analysis of RNAi activities in China’a new “RNAi Valley” by Zicai Liang (Suzhou Ribo Life Science Co., Ltd.)
Strategies to leverage current technology platforms for therapeutics based on peptide hormones, presented by David E. Moller (Lilly Research)
A report on reprogramming the genetic code for discovery of peptide therapeutics by Hiroaki Suga (University of Tokyo).
Why TIDES?
TIDES is the best place to get the information and contacts you need to move your program forward. It’s the only event where you can access in-depth CMC case studies that incorporate manufacturing, analytical, and regulatory experience; meet key players in this field; and see the newest technologies and services in the largest exhibit hall for the oligo and peptide manufacturing industry.
You May Also Like
